Hydrogen Therapy: Not Recommended for Routine Clinical Use
Hydrogen therapy is not currently recommended for any condition in routine clinical practice, as it remains investigational with insufficient evidence to support its use outside of research protocols.
Current Evidence Status
The available evidence consists entirely of early-phase research studies with no established clinical guidelines supporting hydrogen therapy for any medical condition. While preclinical and small human studies suggest potential antioxidant and anti-inflammatory properties, these findings have not translated into guideline-endorsed clinical applications.
Safety Profile
The limited human data suggests hydrogen therapy appears reasonably safe in controlled settings:
- Inhalation studies: 2.4% hydrogen gas inhaled for up to 72 hours in healthy adults showed no clinically significant adverse effects, with stable vital signs, pulmonary function, and laboratory parameters 1
- Acute stroke patients: Intravenous hydrogen-enriched solutions combined with edaravone showed minimal complications (5.3% rate: one case of diarrhea, one cardiac failure) 2
- COPD patients: 30-minute inhalation sessions three times daily for 30 days produced no obvious side effects 3
Investigational Applications
Current research is exploring hydrogen therapy in several conditions, but none have sufficient evidence for clinical recommendation:
- Cardiac arrest/ECPR: The Hydrogen-FAST trial is investigating 2% inhaled hydrogen for 72 hours during extracorporeal cardiopulmonary resuscitation, but this is purely investigational 4
- Acute ischemic stroke: Small studies (n=38) showed feasibility but lack the rigor needed for clinical adoption 2
- COPD: A tiny case series (n=6) showed symptom improvements in some patients but is far too preliminary for recommendations 3
Dosing Considerations (Research Context Only)
When used in research protocols:
- Inhalation: 2-4% hydrogen gas concentration for 20-72 hours via high-flow nasal cannula or mechanical ventilator
- Hydrogen-rich water: No standardized dosing exists
- Intravenous: Hydrogen-enriched saline solutions (concentrations vary by study)
Blood hydrogen concentrations plateau within 20 minutes of inhalation and rapidly decline (to 10% of plateau) within 6-18 minutes after discontinuation 5.
Critical Limitations
The evidence base is fundamentally inadequate for clinical decision-making:
- All studies are small (n=3 to n=38), uncontrolled or poorly controlled
- No large randomized controlled trials exist
- No professional medical societies have issued guidelines endorsing hydrogen therapy
- Mechanisms of action remain incompletely understood
- Long-term safety data are absent
- Optimal dosing, duration, and delivery methods are undefined
Clinical Recommendation
Do not offer hydrogen therapy outside of approved research protocols. If patients inquire about hydrogen therapy, explain that while early research is ongoing, there is currently no evidence supporting its use for any medical condition. Direct interested patients toward established, evidence-based treatments for their specific conditions.
For clinicians involved in research: Hydrogen therapy should only be administered within IRB-approved clinical trials with appropriate safety monitoring, informed consent processes, and data collection protocols 4.